Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Complications

Balancing efficacy with cost: antiemetic control in the pediatric stem cell transplant (SCT) population

Bone Marrow Transplantation volume 25, pages 553–557 (2000)Cite this article

Abstract

We studied the practice patterns regarding intravenous (i.v.) ondansetron in children receiving stem cell transplants (SCT) at The Children's Hospital, Boston to identify cost efficiencies. The pharmacy provided information on material and preparation costs on 36 patients who received i.v. ondansetron during 41 SCT in 1995. We examined the effects of frequency, duration, and route of administration on costs. There were 498 days of ondansetron administration costing $49 083 (95$). Tremendous variation existed in frequency and duration with one third receiving i.v. ondansetron once daily, despite published evidence of equivalence of once a day and divided dosing. A switch to once daily i.v. dosing for all patients would have resulted in ⩾28% savings. The median duration of use was 11 days (range 1–48); placing a cap for 7–10 days based on the length of SCT conditioning regimens, would produce savings of 48–60% over current use. By shifting administration route from i.v. to oral, a savings of 67% over current use, without a cap on duration, would be realized. Identifying areas for cost savings can be achieved after thorough analysis of all the component costs. We demonstrated that significant cost reductions could be realized by simple changes in prescribing practices without jeopardizing efficacy. These savings are achieved by standardizing dosing interval, route of administration and duration of treatment without altering daily dosage or access to an effective antiemetic. Bone Marrow Transplantation (2000) 25, 553–557.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Nightengale BS, Mauch RP . A pharmacoeconomic review of granisetron and ondansetron in the prophylaxis of chemotherapy-induced nausea and vomiting P & T 1998 23: 119–130

    Google Scholar 

  2. Johnson N, Bosanquet N . Cost effectiveness of 5-hydroxytryptamine3 receptor antagonists: a retrospective comparison of ondansetron and granisetron Anti-Cancer Drugs 1995 6: 243–249

    Article  CAS  Google Scholar 

  3. Grunberg SM . Cost-effective use of antiemetics Oncology (Huntingt) 1998 12: (3 Suppl.4) 38–42

    CAS  Google Scholar 

  4. Stewart DJ, Dahrouge S, Coyle D, Evans WK . Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy J Clin Oncol 1999 17: 344–351

    Article  CAS  Google Scholar 

  5. Goldsmith M, Wodinsky H . Controlling costs using evidence-based guidelines: 5-HT3 antagonists as a model Managed Care Cancer 1999 1: 20–24

    Google Scholar 

  6. Grunberg SM . Innovative approaches in the treatment of emesis Support Care Cancer 1997 5: 9–11

    Article  CAS  Google Scholar 

  7. Jones AL, Lee GJ, Bosanquet N . The budgetary impact of 5-HT3-receptor antagonists in the management of chemotherapy-induced emesis Eur J Cancer 1993 29A: 51–56

    Article  Google Scholar 

  8. Fox-Geiman M, Fisher SG, Kiley K et al. Double-blind randomized comparison of oral granisetron, oral ondansetron and IV ondansetron for regimen-related nausea and vomiting (n/v) in patients undergoing stem cell transplants Proc ASCO 1999 18: 592a

    Google Scholar 

  9. Hainsworth JD, Harvey W, Pendergrass K et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy J Clin Oncol 1991 9: 721–728

    Article  CAS  Google Scholar 

  10. Hewitt M, Cornish J, Pamphilon D, Oakhill A . Effective emetic control during conditioning of children for bone marrow transplant using ondansetron, a 5-HT3 antagonist Bone Marrow Transplant 1991 7: 431–433

    CAS  PubMed  Google Scholar 

  11. Hainsworth JD, Hesketh PJ . Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results Semin Oncol 1992 19: (6 Suppl.15) 14–19

    CAS  PubMed  Google Scholar 

  12. Perez EA . Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis Clin Ther 1996 18: 578–590

    Article  CAS  Google Scholar 

  13. Perez EA, Hesketh PJ, Sandbach J et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study J Clin Oncol 1998 16: 754–760

    Article  CAS  Google Scholar 

  14. Gralla RJ, Navari RM, Hesketh PJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy J Clin Oncol 1998 16: 1568–1573

    Article  CAS  Google Scholar 

  15. Frakes LA, Brehm TL, Kosty MP et al. An all oral antiemetic regimen for patients undergoing high dose chemotherapy with peripheral blood stem cell transplant Bone Marrow Transplant 1997 20: 473–478

    Article  CAS  Google Scholar 

  16. Gandara DR, Roila F, Warr D et al. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration Support Care Cancer 1998 6: (3) 237–243

    Article  CAS  Google Scholar 

  17. Beck TM, Ciociola AA, Jones SE et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy Ann Intern Med 1993 118: 407–413

    Article  CAS  Google Scholar 

  18. Spector JI, Lester EP, Chevlen EM et al. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy Oncologist 1998 3: 432–438

    CAS  PubMed  Google Scholar 

  19. Krzakowski M, Graham E, Goedhals L et al. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group Anticancer Drugs 1998 9: 593–598

    Article  CAS  Google Scholar 

  20. Mehta NH, Reed CM, Kuhlman C et al. Controlling conditioning-related emesis in children undergoing bone marrow transplantation Oncol Nurs Forum 1997 24: 1539–1544

    CAS  PubMed  Google Scholar 

  21. Abbott B, Ippoliti C, Bruton J et al. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation Bone Marrow Transplant 1999 23: 265–269

    Article  CAS  Google Scholar 

  22. Orchard PJ, Burns L, Rogosheske T et al. A prospective, randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplant Blood 1998 92: (Suppl.1) 279a

    Google Scholar 

  23. Jurgens H, McQuade B . Ondansetron as prophylaxis for chemotherapy and radiotherapy-induced emesis in children Oncology 1992 49: 279–285

    Article  CAS  Google Scholar 

  24. Spitzer TR, Friedman CJ, Bushnell W et al. Oral granisetron (Kytril) and ondansetron (Zofran) in the prevention of hyperfractionated total body irradiation induced emesis: the results of a double-blind, randomized parallel group study Blood 1998 92: (Suppl.1) 278a

    Google Scholar 

  25. Spitzer TR, Bryson JC, Cirenza E et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total body irradiation J Clin Oncol 1994 12: 2432–2438

    Article  CAS  Google Scholar 

  26. Latreille J, Pater J, Johnston D et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy J Clin Oncol 1998 16: 1174–1178

    Article  CAS  Google Scholar 

  27. Kris MG, Gralla RJ, Clark RA et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin J Clin Oncol 1985 3: 1379–1384

    Article  CAS  Google Scholar 

  28. Italian Group for Antiemetic Research . Ondansetron vs. metoclopramide, both combined with dexamethasone in the prevention of cisplatin-induced delayed emesis J Clin Oncol 1997 15: 124–130

    Article  Google Scholar 

  29. Kris MG, Gralla RJ, Tyson LB et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin J Clin Oncol 1989 7: 108–114

    Article  CAS  Google Scholar 

  30. Roila F, Ballatori E . The efficacy and cost-effectiveness of various antiemetic regimens Curr Opin Oncol 1998 10: 310–315

    Article  CAS  Google Scholar 

  31. Parsons SK, Levine KJ, Hoorntje LE et al. A fiscal review of colony stimulating factor use in pediatric stem cell transplantation: an institution-based analysis (submitted for publication)

  32. Zofran Product Information . Glaxo Wellcome, October 1996

  33. O'Brien BJ, Rusthoven J, Rocchi A et al. Impact of chemotherapy-associated nausea and vomiting on patients’ functional status and on costs: survey of five Canadian centres CMAJ 1993 149: 296–302

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Soukop M, McQuade B, Hunter E et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer Oncology 1992 49: 295–304

    Article  CAS  Google Scholar 

  35. Pai VB, Nahata MC, Koepke J et al. Efficacy and safety of oral ondansetron in the control of acute chemotherapy induced nausea and vomiting (ACINV) Proc ASCO 1999 18: 603a

    Google Scholar 

  36. Hesketh PJ, Beck T, Uhlenhopp M et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen J Clin Oncol 1995 13: 2117–2122

    Article  CAS  Google Scholar 

  37. Holdsworth MT, Raisch DW, Duncan MH et al. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia Ann Pharmacother 1995 29: 16–21

    Article  CAS  Google Scholar 

  38. Beck T, York M, Chang A et al. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy Cancer Invest 1997 15: 297–303

    Article  CAS  Google Scholar 

  39. Berard CM, Mahoney CD . Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting Am J Health-Syst Pharm 1995 52: 1879–1885

    CAS  PubMed  Google Scholar 

  40. Ninane J, Ozkaynak MF, Kurtin P, Siegel SE . Variation in the use of ondansetron as an antiemetic drug in children treated with chemotherapy Med Pediatr Oncol 1995 25: 33–37

    Article  CAS  Google Scholar 

  41. Vermeulen LC, Matuszewski KA, Ratko TA et al. Evaluation of ondansetron prescribing in US academic medical centers Arch Intern Med 1994 154: 1733–1740

    Article  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the contributions of Peter J Blanding, RPh, and Frank Federico, RPh in the preparation of this manuscript. SKP is a Dyson Scholar in Clinical Research at the Dana-Farber Cancer Institute. LEH participated in the International Medical Student Exchange Program between the University of Groningen, the Netherlands, and Harvard Medical School, Boston. KJL was awarded a fellowship from the Harvard Medical School Academic Societies’ Committee on Student Research.

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology, Dana-Farber Cancer Institute, USA

    SK Parsons, LE Hoorntje, KJ Levine, DK Mayer & EC Guinan

  2. Division of Hematology/Oncology, USA

    SK Parsons & EC Guinan

  3. Harvard Medical School, Boston, MA, USA

    SK Parsons, KJ Levine & EC Guinan

  4. Department of Pharmacy, Children's Hospital, USA

    WJ Eichelberger

Authors
  1. SK Parsons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. LE Hoorntje
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. KJ Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. DK Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. WJ Eichelberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. EC Guinan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parsons, S., Hoorntje, L., Levine, K. et al. Balancing efficacy with cost: antiemetic control in the pediatric stem cell transplant (SCT) population. Bone Marrow Transplant 25, 553–557 (2000). https://doi.org/10.1038/sj.bmt.1702179

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702179

Keywords

Search

Advanced search

Quick links